Milestone Pharmaceuticals, Inc. Forecast, price target & analysts
Milestone Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
Milestone Pharmaceuticals, Inc. Classifications & Recommendation
Milestone Pharmaceuticals, Inc. Price Target
| Target Price | $7.14 |
| Price | $0.80 |
| Potential |
797.66%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Milestone Pharmaceuticals, Inc. 2027 .
The average Milestone Pharmaceuticals, Inc. target price is $7.14.
This is
797.66%
register free of charge
$8.40
956.07%
register free of charge
$2.02
153.96%
register free of charge
|
|
| A rating was issued by 13 analysts: 11 Analysts recommend Milestone Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Milestone Pharmaceuticals, Inc. stock has an average upside potential 2027 of
797.66%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.55 | 3.91 |
| 151.94% | ||
| EBITDA Margin | -4,001.94% | -1,585.51% |
| 60.38% | ||
| Net Margin | -4,068.39% | -2,756.06% |
| 32.26% |
9 Analysts have issued a sales forecast Milestone Pharmaceuticals, Inc. 2026 . The average Milestone Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Milestone Pharmaceuticals, Inc. EBITDA forecast 2026. The average Milestone Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Milestone Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Milestone Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.75 | -0.86 |
| 11.94% | 14.67% | |
| P/E | negative | |
| EV/Sales | 17.54 |
9 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast for earnings per share. The average Milestone Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Milestone Pharmaceuticals, Inc....
Current Milestone Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 03 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Aug 20 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 14 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 06 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Dec 16 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Dec 15 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 15 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 03 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Aug 20 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 14 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 06 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Dec 16 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Dec 15 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 15 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
